16:28 , Jan 12, 2018 |  BC Week In Review  |  Company News

Spark unveils gene therapy program for Pompe's

Spark Therapeutics Inc. (NASDAQ:ONCE) said it is developing a preclinical gene therapy for Pompe's disease using its liver-targeting adeno-associated virus (AAV) platform. The therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed...
22:47 , Jan 9, 2018 |  BC Extra  |  Company News

Spark to develop gene therapy for Pompe's

Spark Therapeutics Inc. (NASDAQ:ONCE) said it is developing a preclinical gene therapy for Pompe's disease using its liver-targeting adeno-associated virus (AAV) platform. The therapy, SPK-GAA, will use a novel acid alpha glucosidase (GAA) transgene in-licensed...
07:00 , Jul 20, 2016 |  BC Extra  |  Top Story

Audentes inches up after pricing $75M IPO

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading Wednesday after raising $75 million through the sale of 5 million shares at $15 in an IPO. The...
01:32 , Oct 14, 2015 |  BC Extra  |  Financial News

Audentes raises $65 million in series C

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price;...
02:50 , Dec 3, 2014 |  BC Extra  |  Financial News

Gene therapy play Audentes raises $42.5M

Audentes Therapeutics Inc. (San Francisco, Calif.) raised $42.5 million in a series B round led by Deerfield Management. New investors Sofinnova Ventures and Venrock and existing investors OrbiMed, 5AM Ventures and Versant Ventures also participated....
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Audentes Therapeutics, ReGenX deal

ReGenX granted Audentes exclusive, worldwide rights to use NAV rAAV8 and rAAV9 vectors to develop and commercialize products to treat X-linked myotubular myopathy and Pompe's disease. ReGenX will receive an undisclosed upfront payment and is...
00:18 , Jul 19, 2013 |  BC Extra  |  Financial News

Audentes raises $30 million in series A

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $30 million in a series A round led by OrbiMed Advisors. 5AM Ventures and Versant Ventures also participated. Audentes has two compounds in preclinical development:...